RNS Number : 6545G
UDG Healthcare Public Limited Co.
26 November 2020
Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them
[This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)]
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Brendan McAtamney
|
|
|
|
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR - Chief Executive - UDG Healthcare plc
|
|
b)
|
Initial Notification Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
UDG Healthcare plc
|
|
b)
|
LEI
|
549300IWG5ZPP6B8HH13
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument,
type of
instrument
Identification code
|
Ordinary Shares of €0.05 each in UDG Healthcare plc
ISIN: IE0033024807
|
|
b)
|
Nature of the transaction
|
Additional grant of nominal cost options under the
2019 Performance Share Plan in relation to the year to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
€0.05
|
36,228
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
|
|
e)
|
Date of the transaction
|
25/11/2020
|
|
f)
|
Place of the transaction
|
London Stock Exchange, Main Market
|
|
g)
|
Additional Information
|
Period during which options can be exercised
4 JANUARY 2025 to 4 DECEMBER 2026
|
Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them
[This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)]
|
1
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Nigel Clerkin
|
|
|
|
|
Reason for the notification
|
|
a)
|
Position/status
|
PDMR -Chief Financial Officer - UDG Healthcare plc
|
|
b)
|
Initial Notification Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
UDG Healthcare plc
|
|
b)
|
LEI
|
549300IWG5ZPP6B8HH13
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument,
type of
instrument
Identification code
|
Ordinary Shares of €0.05 each in UDG Healthcare plc
ISIN: IE0033024807
|
|
b)
|
Nature of the transaction
|
Additional grant of nominal cost options under the
2019 Performance Share Plan in relation to the year to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
€0.05
|
12,978
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
|
|
e)
|
Date of the transaction
|
25/11/2020
|
|
f)
|
Place of the transaction
|
London Stock Exchange, Main Market
|
|
g)
|
Additional Information
|
Period during which options can be exercised
4 JANUARY 2025 to 4 DECEMBER 2026
|
For further information, please contact:
Damien Moynagh
General Counsel & Company Secretary
Tel: +353-1-4689000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
DSHFLFSFLDLRFII
|
